ÌÇÐÄ´«Ã½

Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
ÌÇÐÄ´«Ã½

Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial.

ÌÇÐÄ´«Ã½

Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial. European journal of heart failure Saldarriaga, C. I., Zannad, F., McMullan, C. J., Xing, A., Gates, D., Anstrom, K. J., Bonaca, M. P., Corda, S., Ezekowitz, J. A., Lam, C. S., Lewis, E. F., Lindenfeld, J., Mentz, R. J., O'Connor, C., Patel, M., Ponikowski, P., Reddy, Y. N., Rosano, G. M., Senni, M., Udelson, J., Voors, A. A., Butler, J. 2025

Abstract

To describe the baseline characteristics of the participants in the VICTOR (Vericiguat Global Study in Patients with Chronic Heart Failure; NCT05093933) trial and compare them to recent trials in patients with heart failure and reduced ejection fraction (HFrEF).Baseline characteristics were evaluated in 6105 patients randomized to vericiguat or placebo. The mean age of the participants was 67?±?11?years, 23.6% were women, 64.4% were White, and 10.7% were self-identified Black. Overall, 29.1% of participants were enrolled in Latin and South America, 27.8% and 18.5% in Eastern and Western Europe, 14.0% in Asia-Pacific and 10.6% in North America. The mean left ventricular ejection fraction was 30?±?7% and 79% had New York Heart Association class II symptoms. Mean estimated glomerular filtration rate was 70.9?±?24.0?ml/min/1.73?m2. Median N-terminal pro-B-type natriuretic peptide level was 1476 (970-2495) pg/ml and 47.5% of participants had no prior hospitalization for heart failure. Baseline therapy included 94.4% beta-blockers, 94.3% renin-angiotensin system modulation (including 56.0% on an angiotensin receptor-neprilysin inhibitor), 77.7% mineralocorticoid receptor antagonists, 59.1% sodium-glucose cotransporter 2 inhibitors, and 32.9% implantable cardioverter-defibrillators. Overall characteristics were relatively similar to other recent HFrEF trials but the VICTOR trial enrolled a higher proportion of participants receiving contemporary drug and device therapy.The VICTOR trial enrolled the most optimally treated population in a phase III heart failure trial. These features will facilitate assessment of the benefit of vericiguat and elucidate the outcomes of patients on up-to-date medical therapy.

View details for

View details for